Cullen/Frost Bankers, Inc. Janux Therapeutics, Inc. Put Options Transaction History
Cullen/Frost Bankers, Inc.
- $7.21 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding JANX
# of Institutions
187Shares Held
41MCall Options Held
115KPut Options Held
681K-
Ra Capital Management, L.P. Boston, MA9.17MShares$341 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$93.8 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$89.2 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$87.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$79.4 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.55B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...